Search Results
Sep 02, 2026, 08:05 ET Rigel to Participate in Upcoming September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 2, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial
More news about: Rigel Pharmaceuticals, Inc.
Aug 13, 2026, 08:05 ET Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced VEPPANUTM (vepdegestrant)
More news about: Rigel Pharmaceuticals, Inc.
Aug 04, 2026, 16:01 ET Rigel Reports Second Quarter 2026 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 4, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the second quarter ended
More news about: Rigel Pharmaceuticals, Inc.
Jul 28, 2026, 08:05 ET Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results
SOUTH SAN FRANCISCO, Calif., July 28, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2026 financial results after market close on Tuesday, August 4, 2026. Rigel senior management
More news about: Rigel Pharmaceuticals, Inc.
Jul 07, 2026, 08:05 ET Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., July 7, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's
More news about: Rigel Pharmaceuticals, Inc.
Jul 01, 2026, 08:05 ET Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer
SOUTH SAN FRANCISCO, Calif., July 1, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the appointment of Alison L. Hannah, M.D. to
More news about: Rigel Pharmaceuticals, Inc.
Jun 16, 2026, 16:01 ET Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)
SOUTH SAN FRANCISCO, Calif., June 16, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the closing of its license agreement for VEPPANUTM
More news about: Rigel Pharmaceuticals, Inc.
May 27, 2026, 08:05 ET Rigel to Present at the Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 27, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president
More news about: Rigel Pharmaceuticals, Inc.
May 21, 2026, 17:17 ET Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
SOUTH SAN FRANCISCO, Calif., May 21, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the final data from the Phase 3 AcceleRET-Lung
More news about: Rigel Pharmaceuticals, Inc.
May 14, 2026, 08:05 ET Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 14, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial
More news about: Rigel Pharmaceuticals, Inc.
May 12, 2026, 07:00 ET Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer
SOUTH SAN FRANCISCO, Calif., May 12, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that it has entered into an exclusive, global
More news about: Rigel Pharmaceuticals, Inc.
May 05, 2026, 16:01 ET Rigel Reports First Quarter 2026 Financial Results
SOUTH SAN FRANCISCO, Calif., May 5, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the first quarter ended
More news about: Rigel Pharmaceuticals, Inc.
Apr 28, 2026, 08:05 ET Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results
SOUTH SAN FRANCISCO, Calif., April 28, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2026 financial results after market close on Tuesday, May 5, 2026. Rigel senior management will
More news about: Rigel Pharmaceuticals, Inc.
Apr 07, 2026, 08:05 ET Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., April 7, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's
More news about: Rigel Pharmaceuticals, Inc.
Mar 31, 2026, 08:05 ET Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology
SOUTH SAN FRANCISCO, Calif., March 31, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced publication of the final data from the Phase
More news about: Rigel Pharmaceuticals, Inc.
Mar 03, 2026, 16:01 ET Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif., March 3, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the fourth quarter and year
More news about: Rigel Pharmaceuticals, Inc.
Feb 24, 2026, 08:05 ET Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2025 financial results after market close on Tuesday, March 3, 2026. Rigel senior
More news about: Rigel Pharmaceuticals, Inc.
Feb 03, 2026, 08:05 ET Rigel Appoints Michael P. Miller to the Board of Directors
SOUTH SAN FRANCISCO, Calif., Feb. 3, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Michael P. Miller to its Board of Directors. Mr. Miller has more than four decades of experience in commercial
More news about: Rigel Pharmaceuticals, Inc.
Jan 12, 2026, 08:05 ET Rigel Provides Business Update and 2026 Outlook
SOUTH SAN FRANCISCO, Calif., Jan. 12, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today provided a business update including preliminary total
More news about: Rigel Pharmaceuticals, Inc.
Jan 09, 2026, 08:05 ET Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Jan. 9, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's
More news about: Rigel Pharmaceuticals, Inc.
Jan 07, 2026, 08:05 ET Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 7, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president
More news about: Rigel Pharmaceuticals, Inc.
Dec 07, 2025, 09:30 ET Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition
SOUTH SAN FRANCISCO, Calif., Dec. 7, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced updated data from its ongoing Phase 1b study
More news about: Rigel Pharmaceuticals, Inc.
Nov 26, 2025, 08:05 ET Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial
More news about: Rigel Pharmaceuticals, Inc.
Nov 17, 2025, 08:05 ET Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology
SOUTH SAN FRANCISCO, Calif., Nov. 17, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced a peer-reviewed publication in the Journal
More news about: Rigel Pharmaceuticals, Inc.
Nov 12, 2025, 08:05 ET Rigel to Present at the Jefferies Global Healthcare Conference in London
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president
More news about: Rigel Pharmaceuticals, Inc.